Kardigan completes enrollment in two late-stage cardiovascular trials, reports Q3 2026 results
The company finished enrollment in Phase 2b portions of its danicamtiv and ataciguat trials while Phase 3 enrollment continues, with cash of $591.4 million as of September 30, 2026.
SEC filing